Figure 1

A). Generation of α-Synuclein gene transfer animal models and parkin effects on total α-Synuclein levels. Schematic representation of lentiviral clones encoding human α-Synuclein and human wild type and mutant T240R parkin. B). Western blot analysis of striatal brain extracts using 4-12% NuPAGE SDS gel (Invitrogen) probed with parkin (PRK8), and α-Synuclein antibodies and C). Densitometric analysis. D). Western blot analysis of M17 cell extracts infected with T240R mutant parkin and human α-Synuclein using 4-12% NuPAGE SDS gel (Invitrogen) probed with parkin (PRK8), and α-Synuclein antibodies. E). Parkin immnunostaining (PRK-8) of 20 micron-thick rat striatal sections injected with E). lentiviral LacZ (Lv-LacZ), F). lentiviral parkin (Lv-Par), G). Lentiviral α-Synuclein (Lv-Syn) and H). Lentiviral parkin+lentiviral α-Synuclein (Lv-Par+Lv-Syn). Immunoreactivity using human anti-α-Synuclein antibody followed by DAB staining in sections of rat striatum injected with I). lentiviral LacZ, J). lentiviral parkin, K). lentiviral α-Synuclein and L). lentiviral parkin+α-Synuclein. Asterisk is significantly different to LacZ control, ANOVA, with Neumann Keuls multiple comparison N = 4, P < 0.05.